Literature DB >> 14587215

Dystroglycan and muscular dystrophies related to the dystrophin-glycoprotein complex.

Francesca Sciandra1, Manuela Bozzi, Marzia Bianchi, Ernesto Pavoni, Bruno Giardina, Andrea Brancaccio.   

Abstract

Dystroglycan (DG) is an adhesion molecule composed of two subunits, alpha and beta, that are produced by the post-translational cleavage of a single precursor molecule. DG is a pivotal component of the dystrophin-glycoprotein complex (DGC), which connects the extracellular matrix to the cytoskeleton in skeletal muscle and many other tissues. Some muscular dystrophies are caused by mutations of DGC components, such as dystrophin, sarcoglycan or laminin-2, or also of DGC-associated molecules, such as caveolin-3. DG-null mice died during early embriogenesis and no neuromuscular diseases directly associated to genetic abnormalities of DG were identified so far. However, DG plays a crucial role for muscle integrity since its targeting at the sarcolemma is often perturbed in DGC-related neuromuscular disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14587215

Source DB:  PubMed          Journal:  Ann Ist Super Sanita        ISSN: 0021-2571            Impact factor:   1.663


  9 in total

Review 1.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

2.  Understanding the Role of ECM Protein Composition and Geometric Micropatterning for Engineering Human Skeletal Muscle.

Authors:  Rebecca M Duffy; Yan Sun; Adam W Feinberg
Journal:  Ann Biomed Eng       Date:  2016-03-16       Impact factor: 3.934

3.  A novel isoform of delta-sarcoglycan is localized at the sarcoplasmic reticulum of mouse skeletal muscle.

Authors:  Francisco J Estrada; Dominique Mornet; Haydeé Rosas-Vargas; Alexandra Angulo; Manuel Hernández; Viola Becker; Alvaro Rendón; Manuel Ramos-Kuri; Ramón M Coral-Vázquez
Journal:  Biochem Biophys Res Commun       Date:  2005-12-27       Impact factor: 3.575

Review 4.  O-Mannosylation and human disease.

Authors:  Christina M Dobson; Samuel J Hempel; Stephanie H Stalnaker; Ryan Stuart; Lance Wells
Journal:  Cell Mol Life Sci       Date:  2012-11-01       Impact factor: 9.261

5.  New dystrophin/dystroglycan interactors control neuron behavior in Drosophila eye.

Authors:  April K Marrone; Mariya M Kucherenko; Valentyna M Rishko; Halyna R Shcherbata
Journal:  BMC Neurosci       Date:  2011-09-26       Impact factor: 3.288

6.  Hyperthermic seizures and aberrant cellular homeostasis in Drosophila dystrophic muscles.

Authors:  April K Marrone; Mariya M Kucherenko; Robert Wiek; Martin C Göpfert; Halyna R Shcherbata
Journal:  Sci Rep       Date:  2011-07-28       Impact factor: 4.379

7.  A Novel AGRN Mutation Leads to Congenital Myasthenic Syndrome Only Affecting Limb-girdle Muscle.

Authors:  Ying Zhang; Yi Dai; Jing-Na Han; Zhao-Hui Chen; Li Ling; Chuan-Qiang Pu; Li-Ying Cui; Xu-Sheng Huang
Journal:  Chin Med J (Engl)       Date:  2017-10-05       Impact factor: 2.628

8.  Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.

Authors:  Steven J Foltz; Junna Luan; Jarrod A Call; Ankit Patel; Kristen B Peissig; Marisa J Fortunato; Aaron M Beedle
Journal:  Skelet Muscle       Date:  2016-06-02       Impact factor: 4.912

Review 9.  Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening.

Authors:  Paz Ovics; Danielle Regev; Polina Baskin; Mor Davidor; Yuval Shemer; Shunit Neeman; Yael Ben-Haim; Ofer Binah
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.